ZYNE - Zynerba Pharmaceuticals, Inc.
7.20 +0.01 (0.14%)
After hours: 5:26PM EDT
| Previous Close | 7.25 |
| Open | 7.25 |
| Bid | 7.15 x 1300 |
| Ask | 7.20 x 2900 |
| Day's Range | 7.08 - 7.43 |
| 52 Week Range | 5.59 - 15.14 |
| Volume | 338,440 |
| Avg. Volume | 627,842 |
| Market Cap | 126.716M |
| Beta (3Y Monthly) | 4.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.05 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.40 |
- GlobeNewswire•4 days ago
Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Zynerba’s Chief Executive Officer, will present a company overview at the 2018 BIO Investor Forum. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
Oilprice.com•12 days agoBeverage Giants Buying Into The Cannabis Boom
The beverage sector is one of the most profitable in the markets, and now these billion-dollar giants are getting in on the next great North American industry
- InvestorPlace•14 days ago
2 Marijuana Biotechs to Watch
On Sept. 27, the United States Drug Enforcement Agency (DEA) made official a long-awaited decision on a cannabidiol (CBD)-based drug. GW Pharmaceuticals’ (NASDAQ:GWPH) drug Epidiolex was reclassified from Schedule 1 to Schedule 5.
- ACCESSWIRE•14 days ago
The Hottest CBD Stocks
HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...
- GlobeNewswire•19 days ago
Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2018 Cantor Global Healthcare conference. The presentation will take place on October 1, 2018 at 2:55 PM EDT at the InterContinental New York Barclay Hotel. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
- Benzinga•24 days ago
Cantor Fitzgerald's 7 Buys For 7 Biotechs
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...
- Zacks•25 days ago
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
- ACCESSWIRE•26 days ago
CBD Stocks Set to Explode
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...
- Simply Wall St.•26 days ago
What Makes Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) An Attractive Investment?
I’ve been keeping an eye on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...
- GlobeNewswire•last month
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 20th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., L.L.C. on September 5, 2018 at 8:45 AM EDT at the St. Regis New York. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
- InvestorPlace•2 months ago
Zynerba Pharmaceuticals Continues Its 3-Day Rally
The stock went from its closing price of $6.80 on Tuesday and finished the day off sitting at $8.00. This represents an 17%-increase for Zynerba Pharmaceuticals on Wednesday. Now the rally for ZYNE stock is still going strong on Thursday, Aug. 30, 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ZYNE earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Zynerba Pharmaceuticals Inc Earnings Call
- Motley Fool•2 months ago
The Worst-Performing Marijuana Stocks in July
Talk about buzzkills! These five pot stocks all fell by at least 19% last month.
- Associated Press•2 months ago
Zynerba: 2Q Earnings Snapshot
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 89 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa., Aug. 02, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today ...
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher will present a company overview at the 38th Annual Canaccord Genuity Growth Conference on August 8, 2018 at 4:00 PM EDT at the InterContinental Boston. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
- GlobeNewswire•2 months ago
Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
DEVON, Pa., July 31, 2018-- Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host ...
- ACCESSWIRE•3 months ago
This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up
CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.
- InvestorPlace•3 months ago
Market Roasts Shares of Zynerba Pharmaceuticals
Just as shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) were on the way to rebounding back to the $10 level, the stock fell on Friday after the company announced a share issuance. With a 25-percent cut in the ZYNE share price, is the sell-off in this micro-cap biotechnology firm overdone? Zynerba announced a tiny, $32.5 million public offering of its shares: 4.062 million shares at $8 each.
- MarketWatch•3 months ago
Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.
- GlobeNewswire•3 months ago
Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Zynerba Pharmaceuticals, Inc. (ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Zynerba has granted the underwriters a 30-day option to purchase up to 609,375 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.
- Benzinga•3 months ago
Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 19) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Champions Oncology ...
- GlobeNewswire•3 months ago
Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
Zynerba Pharmaceuticals, Inc. (ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Zynerba. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Zynerba intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager.
